Zacks believes the $13.35 billion acquisition will make the company a market leader in the musculoskeletal industry, improving the merged entity’s position. The market is competitive.
But the report also finds pricing pressure and currency headwinds could be threats in the future.
“Zimmer is on its way to achieve market growth based on its strong portfolio and ageing demographics,” according to the report. Zimmer plans to continue global restructuring to streamline it’s business, and Zacks has decided to maintain its “neutral” recommedation for the company.
More articles on devices:
Amedica’s 2Q financial report: 5 key takeways
University of New Mexico names Dr. Anthony Yeung 2014 Distinguished Alumni Award
LDR 2Q revenue up 30.7%, new strategic investments revealed: 11 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
